ADC Therapeutics SA

ADCT has formed an early post-capitulation base in Stage 1 with clear exhaustion after a deep washout. The chart is extreme oversold, and RSI is recovering from lows. Price is tightly holding above the rising 9EMA and 21EMA, confirming support. Mean‐reversion rules in Stage 1 mandate a medium‐term bullish bias and open a buy‐now opportunity at short‐term EMA support.

• ↑Q1 net product revenues rose 15% YoY to $20M, indicating stable demand for Zynlanta.
• ↑$231M cash runway supports trials and operations through 2028, reducing dilution risk.
• ↓Q1 net loss narrowed to $33M vs $38.6M YoY but still indicates negative profitability.